As part of our ongoing series focussing on new registrations in Australia, we have added a product review of Molnupiravir in adult patients with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation and death.
This review discusses pharmacological properties, mechanism of action and major studies featuring Molnupiravir. It also provides commentary and recommendations from Associate Professor Paul Griffin, Director of Infectious Diseases, Mater and Associate Professor of Medicine, University of Queensland.
Please login below to download this issue (PDF)